Diagnosis and Treatment Strategies in Patients With NSCLC With or Without EGFR Mutations.
NCT ID: NCT01525199
Last Updated: 2014-04-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
450 participants
OBSERVATIONAL
2012-05-31
2013-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation in Real World of Molecular Testing and Treatment Patterns for EGFR Mutation in Lung Cancer Patients
NCT03721289
Non-interventional, Prospective Study to Determine Prevalence of EGFR Mutations in Non-small Cell Lung Cancer
NCT04742192
Epidemiological Study to Evaluate the Prevalence of Epidermal Growth Factor Receptor (EGFR) Mutation Status in Patients With Newly Diagnosed Locally Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC)
NCT01081496
Best EGFR-TKI Sequence in NSCLC Harboring EGFR Mutations
NCT04811001
Implementing Circulating Tumor DNA Analysis at Initial Diagnosis to Improve Management of Advanced NSCLC Patients
NCT04912687
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Case
No interventions assigned to this group
Control
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients under 1st line treatment against lung adenocarcinoma.
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Bahía Blanca, Buenos Aires, Argentina
Research Site
Ciudad de Buenos Aires, Buenos Aires, Argentina
Research Site
Junín, Buenos Aires, Argentina
Research Site
La Plata, Buenos Aires, Argentina
Research Site
Lanús, Buenos Aires, Argentina
Research Site
Lomas de Zamora, Buenos Aires, Argentina
Research Site
Mar del Plata, Buenos Aires, Argentina
Research Site
San Carlos de Bolívar, Buenos Aires, Argentina
Research Site
Córdoba, Córdoba Province, Argentina
Research Site
Santa Rosa, La Pampa Province, Argentina
Research Site
La Rioja, La Rioja Province, Argentina
Research Site
Mendoza, Mendoza Province, Argentina
Research Site
Gral. Roca, Río Negro Province, Argentina
Research Site
San Luis, San Luis Province, Argentina
Research Site
Rosario, Santa Fe Province, Argentina
Research Site
Santa Fe, Santa Fe Province, Argentina
Research Site
San Miguel de Tucumán, Tucumán Province, Argentina
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NIS-OAR-XXX-2011/1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.